Slovenia's Salus cons net profit rises 39.6% y/y in Q1

Consolidated net sales revenue went up by an annual 17% to 164.9 million euro in the three months through March 2024, Salus said in a filing with the Ljubljana Stock Exchange on Tuesday.

The group's operating profit increased to 18.6 million euro from 13.6 million euro in January-March 2023, while EBITDA totalled 6.8 million euro, up from 4.7 million euro in the like period of last year.

Ljubljana-based Salus is one of Slovenia's leading wholesalers of pharmaceutical and medical products.

($ = 0.92331 euro)